Journal article
Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
- Juillerat P Division of Gastroenterology and Hepatology, University of Lausanne, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
- Christen-Zäch S
- Troillet FX
- Gallot-Lavallée S
- Pannizzon RG
- Michetti P
- 2007-09-08
Published in:
- Dermatology (Basel, Switzerland). - 2007
Adult
Antibodies, Monoclonal
Colitis, Ulcerative
Dermatologic Agents
Female
Humans
Infliximab
Pyoderma Gangrenosum
English
We report the case of a 19-year-old woman who developed an acute disseminated pyoderma gangrenosum (PG) during a severe flare of ulcerative colitis (UC). She was successfully treated with a 3-dose regimen of the anti-tumor-necrosis-factor-alpha antibody infliximab. The literature on the effectiveness of this biological agent was reviewed, including 8 other cases of UC-associated PG and 77 cases of Crohn's-disease-associated PG. This case report and the review of the literature demonstrate that infliximab can be successfully used to treat patients with PG associated with inflammatory bowel diseases.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1159/000106584
- PMID 17823524
- Persistent URL
- https://folia.unifr.ch/global/documents/282958
Statistics
Document views: 31
File downloads: